(HealthDay News) — The TIMI (Thrombolysis in Myocardial Infarction) Risk Score for Secondary Prevention (TRS 2°P) is an accurate predictor of atherothrombotic disease among patients with type 2 diabetes, according to a study published online in Diabetes Care.

Brian A. Bergmark, MD, from Brigham and Women’s Hospital in Boston, and colleagues assessed the TRS 2°P in patients with type 2 diabetes by comparing baseline TRS 2°P in a cohort of 16,488 patients (participating in SAVOR-TIMI 53) with type 2 diabetes and high cardiovascular (CV) risk or established CV disease.

The researchers found that TRS 2°P resulted in a robust risk gradient for the composite outcome of CV death, myocardial infarction (MI), and ischemic stroke. Among the full cohort, two-year event rates were 0.9% in the lowest- and 19.8% in the highest-risk groups (Ptrend < 0.001). Within subgroups, including all coronary artery disease (CAD), CAD without prior MI, CAD with prior MI, peripheral artery disease, and prior stroke, a clear risk gradient was detected (Ptrend < 0.001 for each). Similar results were seen with the type 2 diabetes cohort from the REACH Registry (goodness-of-fit P = 0.78).

Continue Reading

“The expanded TRS 2°P provides a practical and well-calibrated risk prediction tool for patients with type 2 diabetes,” the authors write.

Several authors disclosed financial ties to pharmaceutical companies, including AstraZeneca and Bristol-Myers Squibb, which funded the study.

Related Articles


Bergmark BA, Bhatt DL, Braunwald E, et al. Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. Diab Care 2017 Nov; dc171736. https://doi.org/10.2337/dc17-1736